Ozempic® and hair loss

Three official documents, one mention

Regulators in the United States, the European Union and Canada each publish their own product information for Ozempic®. They draw on largely the same clinical programme in adults with type 2 diabetes but organise adverse reactions differently, so it is worth looking at all three before drawing a conclusion.

Reading a postmarketing listing

Section 6.2 of the US label collects reactions reported voluntarily after semaglutide reached the market. The label itself explains the limit: because the size of the population behind these reports is unknown, the frequency cannot be estimated reliably and a causal link to the drug cannot be shown ^[1].

A listing there means enough reports reached the manufacturer and the FDA to be noted. It does not mean hair loss is common on Ozempic®, and it does not prove that the medicine caused any individual case.

What semaglutide studies add

The clearest trial numbers for the same molecule come from the Wegovy® label, where semaglutide is used at higher doses for weight management. In a pool of three adult studies, hair loss was reported in 3.3% of people on Wegovy® 2.4 mg and 1% on placebo. The gap was wider in women (4% against 2%) than in men (0.9% against none). With Wegovy® 7.2 mg it rose to 5.8%. The label describes these reactions as associated with weight reduction ^[4].

A 2026 systematic review and meta-analysis pooled nine interventional studies with 4,114 people on GLP-1 medicines. Hair loss was about three times as likely as on placebo (risk ratio 3.25), and the pooled event rate was 3.9% ^[5]. Most of the evidence came from weight-management trials, the analysis mixed several GLP-1 medicines, and hair loss was counted as a reported adverse event rather than measured, so it cannot give an Ozempic®-specific rate for people with type 2 diabetes.

How a diabetes medicine could be linked to shedding

What the labels support: the Wegovy® label links hair loss to weight reduction rather than to a direct effect on hair ^[4]. Ozempic® also lowers body weight, though its label is written around blood sugar control, not weight loss ^[1].

A proposed but unmeasured route: telogen effluvium, a pattern in which many hair follicles switch into their resting phase at once after a physical stressor. Cleveland Clinic lists rapid weight loss and diets short on protein among the triggers ^[7]. No Ozempic® study has measured this directly.

General background: hair follicles cycle continuously, and anything that strains the body, from a fever to surgery, can push extra follicles into shedding at the same time ^[6].

Other reasons hair thins

MedlinePlus groups the common causes into a few families, and several are as likely as the medicine in any one person ^[6]:

• Inherited pattern thinning, which increases with age in both men and women.
• Physical or emotional stress: high fever, severe infection, childbirth, major surgery or illness, sudden blood loss.
• Crash diets, especially those low in protein.
• Other medicines, including retinoids, birth control pills, beta-blockers, calcium channel blockers, some antidepressants and NSAIDs.
• Thyroid disease, anaemia, hormone changes and autoimmune conditions such as alopecia areata or lupus.
• Tight hairstyles, heavy shampooing and blow-drying, or scalp infections.

Timing, and what usually helps

Stress-related shedding tends to appear two to three months after the trigger; Cleveland Clinic notes that acute telogen effluvium lasts under six months and resolves in most cases, with regrowth expected afterwards ^[7]. MedlinePlus says hair often comes out in handfuls during washing or combing, and that the shedding fades over six to eight months ^[6].

For shedding linked to illness or medicines, MedlinePlus says treatment is usually not needed and hair grows back once the cause passes; a change of hairstyle can disguise thinning in the meantime ^[6]. Cleveland Clinic suggests avoiding very restrictive diets, managing stress and sleeping well, and checking with a clinician before starting supplements ^[7]. Neither source gives guidance specific to Ozempic®, so any change to your diabetes treatment is a conversation for your prescriber.

Ozempic® details that matter here

Ozempic® is a once-weekly injection approved in the US for adults with type 2 diabetes, including to lower cardiovascular and kidney risks in some of them ^[1]. Its label starts at 0.25 mg and moves up in steps of at least four weeks; it does not report hair loss by dose step ^[1]. Because shedding often trails its trigger by months, the timing of dose changes, weight change and any illness is useful information to bring to an appointment.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.